Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tusamitamab ravtansine + sintilimab + cisplatin + pemetrexed
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination regimen consisting of four agents: **tusamitamab ravtansine** (a CEACAM5-directed antibody-drug conjugate), **sintilimab** (an anti-PD-1 monoclonal antibody), **cisplatin** (a platinum-based chemotherapeutic), and **pemetrexed** (an antifolate chemotherapeutic). Tusamitamab ravtansine delivers a cytotoxic maytansinoid payload to cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), inhibiting microtubule assembly, while sintilimab blocks PD-1 signaling to augment antitumor immune responses. Cisplatin and pemetrexed interfere with DNA synthesis and function. This combination is being investigated in clinical trials primarily for advanced/metastatic non-squamous non-small cell lung cancer, particularly in tumors with high CEACAM5 expression[3][4][5][6].
- Brand names
- None identified for this specific combination
- Other names
- None identified for this specific combination
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on tusamitamab ravtansine + sintilimab + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tusamitamab ravtansine + sintilimab + cisplatin + pemetrexed.